Brain metastases (BMs) from solid tumors: one biology, one drug and a specific activityThe survival of patients following the development of brain metastasis (BM) is measured in weeks to months, even if a considerable variability is observed in relation to the histotype, the size, the number and site of the brain spreading, as well as the performance status of single patient, the symptoms and the burden of disease. Whereas the overall 2-year survival rate in patients with BM is 8.1%, 2-year survival after diagnosis of BM is less than 2% in patients with SCLC, but as high as 24% in patients with ovarian cancer (1). The findings from the last 5 years of patients with oligometastases to the brain treated primarily with local surgical or radiation therapy reveal a more encouraging median overall survival of 16 months from the time of BM diagnosis (2). Despite the evolution